Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors ...
Key Points Interested in ALX Oncology Holdings Inc.? Here are five stocks we like better. ALX Oncology expects key data ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients ...
The U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 ...
The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery. The Food and Drug Administration (FDA) granted a ...
New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.
AstraZeneca and Daiichi Sankyo have officially escalated the competition in HER2-positive breast cancer treatment. Thursday, AZ and Daiichi said the FDA has approved their rising star Enhertu for ...
PITTSBURGH, Pa. (Ivanhoe Newswire) - One in eight women will be diagnosed with breast cancer in their lifetime - the second leading cause of cancer death for women, behind lung cancer but after years ...
Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support ENHERTU as the potential new standard of care in previously treated patients ...
Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...
The approval covers the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results